Apolipoprotein E4-Mediated Metabolic Dysfunction Correction via Liver X Receptor Agonism

NR1H2 (LXRβ), APOE metabolomics market 40% proposed
Composite
38%
Novelty
40%
Feasibility
25%
Impact
50%
Mechanistic
50%
Druggability
55%
Safety
15%
Confidence
50%

Mechanistic description

Apolipoprotein E4-Mediated Metabolic Dysfunction Correction via Liver X Receptor Agonism

Evidence for (4)

  • ApoE4 knock-in mice exhibit accumulation of neutral lipids and cholesterol esters in astrocytes, with impaired lipid efflux

    PMID:26282200

  • LXR agonist (GW3965) treatment in ApoE4-targeted replacement mice reduces amyloid deposition and improves cognitive performance

    PMID:20164442

  • Metabolomic profiling reveals distinct lipidomic signatures in ApoE4 vs. ApoE3 carriers, including elevated saturated free fatty acids

    PMID:30108022

  • ABCA1 expression is reduced in ApoE4 astrocytes, limiting cholesterol efflux to ApoE particles

    PMID:25542525

Evidence against (4)

  • LXR agonists induce lipogenesis - GW3965 increases SREBP1c expression, leading to hepatic steatosis

    PMID:24309171

  • All advanced LXR agonist programs terminated - Novartis LXR-623 Phase I failed (2010), VTP-45543 and others discontinued

  • ApoE4 carriers may not have dysfunction but different function - lipid droplet accumulation may be compensatory

    PMID:30591436

  • LXR agonists have failed in metabolic syndrome trials, limiting translational potential

    PMID:25470522